Real-world lenvatinib use in metastatic thyroid cancer: early dose intensity and side effect profile in an Australian centre
{{output}}
Objective: Lenvatinib is a multi-kinase inhibitor approved in radioiodine-refractory thyroid cancer based on results of a phase III trial. Real-world data have emphasised concerns regarding tolerability of the starting dose (24 m... ...
